Boehringer Ingelheim Launches One Medicine R&D Platform in Partnership with Veeva Systems

Boehringer Ingelheim, the German pharmaceutical giant, has unveiled its much-anticipated One Medicine platform, developed in collaboration with software firm Veeva Systems. This innovative research and development (R&D) tool aims to revolutionize the company's product development process by integrating clinical, regulatory, and quality data streams.

One Medicine Platform: Streamlining Drug Development

The One Medicine platform, powered by Veeva's development cloud, is designed to enhance Boehringer Ingelheim's ability to bring new medicines to market more efficiently. By consolidating various aspects of the drug development process, including clinical trial management, quality control, and payments, the platform promises to boost collaboration and streamline workflows across the company's R&D operations.

Oliver Fink, Boehringer's head of learning, process and digitalization, emphasized the platform's potential impact: "Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world."

Long-Standing Partnership Bears Fruit

The launch of One Medicine marks a significant milestone in the ongoing partnership between Boehringer Ingelheim and Veeva Systems. The collaboration, which began in March 2022, builds upon a decades-long commercial relationship between the two companies. This latest development underscores the growing importance of digital solutions in pharmaceutical R&D.

Veeva's technology has gained widespread adoption in the pharmaceutical industry, with over 450 companies utilizing its services. Notable clients include industry leaders such as Merck, Eli Lilly, and contract research organizations (CROs) like Parexel and Fortrea.

Broader Industry Trends in R&D Digitalization

The introduction of One Medicine reflects a broader trend in the pharmaceutical industry towards digital transformation and data integration. As companies seek to reduce time-to-market for new drugs and improve research efficiency, platforms that can unify disparate data sources and processes are becoming increasingly valuable.

In a related development, Veeva recently partnered with Fortrea and regulatory review company Advarra in January 2024. This collaboration aims to further streamline clinical trials and reduce administrative burdens, highlighting the ongoing efforts to optimize drug development processes across the industry.